Crizotinib-d9 hydrochloride | MedChemExpress (MCE)
Crizotinib-d9 hydrochloride is deuterated labeled Crizotinib hydrochloride (HY-50878A). Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition[1][2][3].
| Trivial name | Crizotinib-d9 hydrochloride |
| Catalog Number | HY-50878AS |
| Alternative Name(s) | PF-02341066-d9 hydrochloride |
| Research Area | Cancer |
| Purity | ≥98.0% |
| SMILES | NC1=C(C=C(C=N1)C2=CN(N=C2)C3(C([2H])(C([2H])([2H])NC([2H])([2H])C3([2H])[2H])[2H])[2H])O[C@H](C)C4=C(C=CC(F)=C4Cl)Cl.Cl |
| Size | 1 mg |
| Supplier Page | https://www.medchemexpress.com/crizotinib-d9-hydrochloride.html |